Surface Oncology in brief
Surface Oncology is an unlisted company in the Biotechnology industry, based in the USA. It was founded in 2014. In its latest reported year it had sales of $126 M and a net profit of $59 M, about 47 cents of profit for every dollar of sales.
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Surface Oncology
Surface Oncology is a Clinical and Preclinical Pipeline of Immune Enhancing Antibody company candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies. The company annual revenue is 126.16 million USD and 76 employees as on 2020. The headquarters is in USA.
Surface Oncology timeline
- 2014
- 🏁· approximateFounded
Events of Surface Oncology from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Surface Oncology
- Acquisitions and changes
- No longer listed: ticker SURF is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #4,108 (Jan 2020) · #2,985 (Jan 2021) · #3,804 (Jan 2022) · #5,112 (Dec 2022) · #4,620 (Jul 2023)
Annual results
- Revenue
- $126 M
- Operating income
- —
- Net income
- $59 M
H-1B hiring at Surface Oncology#
1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $188 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Director, GMP and QAValidation Engineers | 1 | $188 K |
Where: Cambridge, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2022 | 1 | 1 | $188 K | 1 |
| FY2021 | 3 | 3 | $101 K | 3 |
How Surface Oncology compares in Biotechnology
- Revenue$126 M · higher than 72% of 647
- Net margin47.0% · higher than 97% of 408
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Surface Oncology🇺🇸 | $59 M | — | 47.0% | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
How current the figures are
- Market cap:
- Jul 30, 2023 (last known)
- Profile updated:
- Nov 14, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Surface Oncology? Verify and update this profile — free
Show Surface Oncology's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.